NASDAQ:ATXI - Avenue Therapeutics Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $4.79 +0.08 (+1.70 %) (As of 05/24/2019 08:07 AM ET)Previous Close$4.71Today's Range$4.67 - $4.8752-Week Range$2.08 - $6.82Volume15,700 shsAverage Volume34,878 shsMarket Capitalization$79.32 millionP/E RatioN/ADividend YieldN/ABeta-0.8 ProfileAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Avenue Therapeutics, Inc., a specialty pharmaceutical company, acquires, licenses, develops, and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, which is in Phase III clinical trials to treat moderate to moderately severe post-operative pain. The company was founded in 2015 and is based in New York, New York. Receive ATXI News and Ratings via Email Sign-up to receive the latest news and ratings for ATXI and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ATXI Previous Symbol CUSIPN/A CIK1644963 Webhttp://www.avenuetx.com/ Phone781-652-4500Debt Debt-to-Equity RatioN/A Current Ratio3.16 Quick Ratio3.16Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.23 per share Price / Book3.89Profitability EPS (Most Recent Fiscal Year)($2.10) Net Income$-21,550,000.00 Net MarginsN/A Return on Equity-326.16% Return on Assets-183.27%Miscellaneous Employees6 Outstanding Shares16,559,000Market Cap$79.32 million Next Earnings Date8/13/2019 (Estimated) OptionableNot Optionable Avenue Therapeutics (NASDAQ:ATXI) Frequently Asked Questions What is Avenue Therapeutics' stock symbol? Avenue Therapeutics trades on the NASDAQ under the ticker symbol "ATXI." How were Avenue Therapeutics' earnings last quarter? Avenue Therapeutics Inc (NASDAQ:ATXI) issued its quarterly earnings results on Monday, May, 13th. The company reported ($0.82) earnings per share for the quarter, missing the consensus estimate of ($0.43) by $0.39. View Avenue Therapeutics' Earnings History. When is Avenue Therapeutics' next earnings date? Avenue Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, August 13th 2019. View Earnings Estimates for Avenue Therapeutics. What price target have analysts set for ATXI? 2 brokerages have issued 1-year target prices for Avenue Therapeutics' stock. Their predictions range from $10.00 to $11.00. On average, they anticipate Avenue Therapeutics' share price to reach $10.50 in the next twelve months. This suggests a possible upside of 119.2% from the stock's current price. View Analyst Price Targets for Avenue Therapeutics. What is the consensus analysts' recommendation for Avenue Therapeutics? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Avenue Therapeutics in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Avenue Therapeutics. Has Avenue Therapeutics been receiving favorable news coverage? News headlines about ATXI stock have been trending positive recently, InfoTrie Sentiment Analysis reports. The research group identifies positive and negative news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Avenue Therapeutics earned a daily sentiment score of 2.6 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the company's share price in the immediate future. Who are some of Avenue Therapeutics' key competitors? Some companies that are related to Avenue Therapeutics include Merus (MRUS), Kadmon (KDMN), ImmunoGen (IMGN), Immune Design (IMDZ), Dova Pharmaceuticals (DOVA), Molecular Templates (MTEM), Geron (GERN), Athersys (ATHX), resTORbio (TORC), TapImmune (MRKR), Concert Pharmaceuticals (CNCE), PhaseBio Pharmaceuticals (PHAS), Protagonist Therapeutics (PTGX), Urovant Sciences (UROV) and Constellation Pharmaceuticals (CNST). What other stocks do shareholders of Avenue Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Avenue Therapeutics investors own include Sorrento Therapeutics (SRNE), Corbus Pharmaceuticals (CRBP), CytomX Therapeutics (CTMX), Smart Global (SGH), AcelRx Pharmaceuticals (ACRX), Agile Therapeutics (AGRX), Allena Pharmaceuticals (ALNA), America First Multifamily Investors (ATAX), Anavex Life Sciences (AVXL) and CymaBay Therapeutics (CBAY). Who are Avenue Therapeutics' key executives? Avenue Therapeutics' management team includes the folowing people: Dr. Lindsay Allan Rosenwald, Exec. Chairman (Age 64)Dr. Lucy Lu, Pres, CEO & Director (Age 44)Mr. Joseph Walter Vazzano, CFO, Principal Financial Officer & Company Sec. (Age 35)Dr. Scott A. Reines, Interim Chief Medical Officer (Age 72) When did Avenue Therapeutics IPO? (ATXI) raised $30 million in an IPO on Tuesday, June 27th 2017. The company issued 5,000,000 shares at a price of $5.00-$7.00 per share. Oppenheimer acted as the underwriter for the IPO and National Securities Corp. was co-manager. Who are Avenue Therapeutics' major shareholders? Avenue Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Opaleye Management Inc. (4.83%), National Asset Management Inc. (0.36%), Spark Investment Management LLC (0.18%) and Renaissance Technologies LLC (0.07%). Company insiders that own Avenue Therapeutics stock include Jeffrey Paley, Lindsay A Md Rosenwald and Neil Herskowitz. View Institutional Ownership Trends for Avenue Therapeutics. Which major investors are selling Avenue Therapeutics stock? ATXI stock was sold by a variety of institutional investors in the last quarter, including National Asset Management Inc.. View Insider Buying and Selling for Avenue Therapeutics. Which major investors are buying Avenue Therapeutics stock? ATXI stock was purchased by a variety of institutional investors in the last quarter, including Opaleye Management Inc., Spark Investment Management LLC and Renaissance Technologies LLC. Company insiders that have bought Avenue Therapeutics stock in the last two years include Jeffrey Paley, Lindsay A Md Rosenwald and Neil Herskowitz. View Insider Buying and Selling for Avenue Therapeutics. How do I buy shares of Avenue Therapeutics? Shares of ATXI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Avenue Therapeutics' stock price today? One share of ATXI stock can currently be purchased for approximately $4.79. How big of a company is Avenue Therapeutics? Avenue Therapeutics has a market capitalization of $79.32 million. The company earns $-21,550,000.00 in net income (profit) each year or ($2.10) on an earnings per share basis. Avenue Therapeutics employs 6 workers across the globe. What is Avenue Therapeutics' official website? The official website for Avenue Therapeutics is http://www.avenuetx.com/. How can I contact Avenue Therapeutics? Avenue Therapeutics' mailing address is 2 GANSEVOORT STREET 9TH FLOOR, NEW YORK NY, 10014. The company can be reached via phone at 781-652-4500 or via email at [email protected] MarketBeat Community Rating for Avenue Therapeutics (NASDAQ ATXI)Community Ranking: 2.2 out of 5 ( )Outperform Votes: 120 (Vote Outperform)Underperform Votes: 152 (Vote Underperform)Total Votes: 272MarketBeat's community ratings are surveys of what our community members think about Avenue Therapeutics and other stocks. Vote "Outperform" if you believe ATXI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ATXI will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 5/24/2019 by MarketBeat.com StaffFeatured Article: Average Daily Trade Volume - What You Need to Know Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.